UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial

Haematologica (Roma), 2020-12, Vol.105 (12), p.2868-2871

2020

Volltextzugriff (PDF)

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

Blood, 2024-07, Vol.144 (4), p.392-401

2024

Volltextzugriff (PDF)

The role of high‐dose chemotherapy and autologous stem cell transplant for treatment‐naΪve patients with peripheral T‐cell lymphoma: a systematic review of the literature

British journal of haematology, 2017-08, Vol.178 (3), p.476-479

2017

Volltextzugriff (PDF)

Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study

Bone marrow transplantation (Basingstoke), 2022, Vol.57 (1), p.144-144

2022

Volltextzugriff (PDF)

Survival outcomes for extranodal natural-killer T-cell lymphoma – Authors' reply

The Lancet. Haematology, 2020-06, Vol.7 (6), p.e442-e442

2020

Volltextzugriff (PDF)

Guideline for the treatment of chronic lymphocytic leukaemia

British journal of haematology, 2018-08, Vol.182 (3), p.344-359

2018

Volltextzugriff (PDF)

Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum

Rheumatology advances in practice, 2022, Vol.6 (2), p.rkac046-rkac046

2022

Volltextzugriff (PDF)

Combining BCL-XL Inhibition with Brentuximab Vedotin to Overcome Chemoresistance in EBV-Related T/NK Lymphoma

Blood, 2023-11, Vol.142 (Supplement 1), p.5784-5784

2023

Volltextzugriff (PDF)

Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison

Blood, 2023-11, Vol.142 (Supplement 1), p.1733-1733

2023

Volltextzugriff (PDF)

Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.6618-6620

2022

Volltextzugriff (PDF)

Flowrna in the Diagnosis of EBV-Related Lymphoproliferative Disease

Blood, 2023-11, Vol.142 (Supplement 1), p.3660-3660

2023

Volltextzugriff (PDF)

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom

Blood, 2019-11, Vol.134 (Supplement_1), p.3482-3482

2019

Volltextzugriff (PDF)

frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS7590-TPS7590

2022

Volltextzugriff (PDF)

The role of high-dose chemotherapy and autologous stem cell transplant for treatment-nave patients with peripheral T-cell lymphoma: a systematic review of the literature

British journal of haematology, 2017-08, Vol.178 (3), p.476

2017

Volltextzugriff (PDF)

Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice

Annals of Lymphoma, 2021-09, Vol.5, p.23-23

2021

Volltextzugriff (PDF)

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Blood, 2022-11, Vol.140 (Supplement 1), p.1775-1777

2022

Volltextzugriff (PDF)

Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma

Biology of blood and marrow transplantation, 2016-07, Vol.22 (7), p.1234-1241

2016

Volltextzugriff (PDF)

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood, 2020-11, Vol.136 (Supplement 1), p.18-19

2020

Volltextzugriff (PDF)

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Blood, 2023-11, Vol.142 (Supplement 1), p.3085-3085

2023

Volltextzugriff (PDF)

Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

Blood, 2021-11, Vol.138 (Supplement 1), p.129-129

2021

Volltextzugriff (PDF)

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Blood, 2020-11, Vol.136 (Supplement 1), p.17-18

2020

Volltextzugriff (PDF)

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Blood, 2020-11, Vol.136 (Supplement 1), p.27-28

2020

Volltextzugriff (PDF)

1 – 25 von 279

Suche als RSS-Feed

Aktive Filter

ThemaAged, 80 And Over

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(236)
Mit Volltextzugriff
(229)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

The role of high‐dose chemotherapy and autologous stem cell transplant for treatment‐naΪve patients with peripheral T‐cell lymphoma: a systematic review of the literature

Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study

Survival outcomes for extranodal natural-killer T-cell lymphoma – Authors' reply

Guideline for the treatment of chronic lymphocytic leukaemia

Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum

P648: REAL‐WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST‐LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY

Combining BCL-XL Inhibition with Brentuximab Vedotin to Overcome Chemoresistance in EBV-Related T/NK Lymphoma

Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison

Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

Flowrna in the Diagnosis of EBV-Related Lymphoproliferative Disease

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom

frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma

The role of high-dose chemotherapy and autologous stem cell transplant for treatment-nave patients with peripheral T-cell lymphoma: a systematic review of the literature

Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Aktive Filter

Suchergebnisse filtern